Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 09:25 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease
NCT06046248 · Northside Hospital, Inc. · PHASE2 · suspended · last registry update 2026-10-16 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Lack of funding and slow accrual” | – | Registry record, Northside Hospital, Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ROCK2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-08-18Phase 3 first posted: Sanofi, Belumosudil (NCT07771439)
- 2026-08-06Results posted on the registry: Kowa Research Institute, Inc., Ripasudil + Placebo (NCT05528172)
- 2026-02-12Also stopped (withdrawn): Kadmon, a Sanofi Company, Belumosudil (NCT05567406)
- 2026-01-02Results posted on the registry: Laboratoires Thea, T4090 0.2% + T4090 0.3% (NCT06394973)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision